Does chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer?
This analysis could not confirm the hypothesis that Chr-17 polysomy in HER2-nonamplified patients improved chemotherapy outcome when lapatinib is added as a HER2-targeted treatment.
This study showed that the conditioned medium of the HS-MSCs exerted a suppressive effect on tumor progression and malignancy, suggesting that hyperthermia enables tumor stromal cells to provide a sensitizing environment for tumor cells to undergo cell death.